CBER Anthrax Vaccine Development: Licensable Product Anticipated In 2003
The Laboratory of Enteric & Sexually Transmitted Diseases in FDA's Center for Biologics Evaluation & Research expects to create a licensable anthrax vaccine by summer 2003
You may also be interested in...
FDA's final rule allowing drug approvals based on animal efficacy studies will permit more than one drug to be approved for an indication without a clear demonstration of superiority over existing products
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials